Framingham, Massachusetts, United States GTC Biotherapeutics is the famous Corporate Investor, which was founded in 1993. The leading representative office of defined Corporate Investor is situated in the Framingham. The fund was located in North America if to be more exact in United States.
The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2012. The important activity for fund was in 2004. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the GTC Biotherapeutics, startups are often financed by National Institutes of Health. The meaningful sponsors for the fund in investment in the same round are Wharton Capital, Sorenson Development. In the next rounds fund is usually obtained by WT Investment Advisors Fund, Unilever Ventures, Sorenson Development.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Merrimack Pharmaceuticals. We can highlight the next thriving fund investment areas, such as Biotechnology, Health Care.
Related Funds
| Fund Name | Location |
| Amazon Corporate Holdings | Central, Central Region, Singapore |
| Bluefrog Interactive | - |
| Consensus Asset Management | Mölndal, Sweden, Vastra Gotaland |
| Cooee Technology | China, Shanghai, Xuhui |
| IncubAsia Ventures | Central, Central Region, Singapore |
| Indigo Capital | England, London, United Kingdom |
| MW EAGLEWOOD | England, London, United Kingdom |
| OYD Capital | Beijing, Beijing, China |
| Shenzhen Qianhai Bochuang Private Equity Fund | - |
| Wasatch Advisors | Salt Lake City, United States, Utah |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Merrimack Pharmaceuticals | $28M | 05 May 2004 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Merrimack Pharmaceuticals | $28M | 05 May 2004 | Cambridge, Massachusetts, United States |
